3-(叔丁基)-1-甲基-1H-吡唑-5-羧酸乙酯 | 133261-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(叔丁基)-1-甲基-1H-吡唑-5-羧酸乙酯
• 中文别名: 1-甲基-3-叔丁基吡唑-5-甲酸乙酯
• 英文名称: 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid ethyl ester
• 英文别名: ethyl 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylate；ethyl 5-tert-butyl-2-methylpyrazole-3-carboxylate
• CAS: 133261-10-6
• 化学式: C₁₁H₁₈N₂O₂
• mdl: MFCD00085059
• 分子量: 210.276
• InChiKey: JCOHRMJIHAFFBC-UHFFFAOYSA-N

物化性质

• 沸点：
  116°C 15mm

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.636
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2933199090

SDS

Name:	Ethyl 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylate tech Material Safety Data Sheet
Synonym:
CAS:	133261-10-6

Section 1 - Chemical Product MSDS Name:Ethyl 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylate tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
133261-10-6	Ethyl 3-(tert-butyl)-1-methyl-1H-pyraz		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 133261-10-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 116 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H18N2O2
Molecular Weight: 210

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 133261-10-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 3-(tert-butyl)-1-methyl-1H-pyrazole-5-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 133261-10-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 133261-10-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 133261-10-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(叔丁基)-1-甲基-1H-吡唑-5-羧酸乙酯 在 磺酰氯 、 草酰氯 、 水 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 5.25h， 生成 5-tert-butyl-4-chloro-2-methyl-2H-pyrazole-3-carboxylic acid (6-bromo-3-nitro-pyridin-2-yl)-amide
  参考文献：
  名称：

  SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS

  摘要：

  本发明涉及替代的氮杂双环咪唑衍生物，含有它们的药物组合物以及它们在治疗由TRP M8调节的疾病和症状中的用途，包括但不限于炎症性疼痛、炎症性过敏症、炎症性过敏性疾病、神经病性疼痛、神经性寒冷痛觉过敏、炎症性体感过敏、炎症性内脏过敏、受寒加重的心血管疾病和受寒加重的肺部疾病。

  公开号：

  US20110218197A1
• 作为产物：
  描述：

  三甲基乙酰基丙酮酸乙酯 、 甲基肼 在 EtOAc-hexanes 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 3-(叔丁基)-1-甲基-1H-吡唑-5-羧酸乙酯
  参考文献：
  名称：

  Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators

  摘要：

  本发明涉及替代的氮杂双环咪唑衍生物、包含它们的制药组合物以及它们在治疗受TRP M8调节的疾病和症状中的应用，包括但不限于炎症性疼痛、炎症性过敏症、炎症性过敏症状、神经病性疼痛、神经病性冷痛觉、炎症性体表过敏症、炎症性内脏过敏症、受寒冷加重的心血管疾病和受寒冷加重的肺部疾病。

  公开号：

  US08680098B2

文献信息

• [EN] NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2009071707A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particularly, to a compound according to formula (I), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof or isotopic variants thereof, stereoisomers or tautomers thereof. The invention extends to compositions, including pharmaceutical compositions, and corresponding uses thereof, and methods of prophylaxis and treatment involving the same.

  本发明涉及一类抑制PDElA的化合物，PDElA是一种参与软骨降解、关节退化以及涉及该降解和/或炎症的疾病调控的磷酸二酯酶，特别是一种符合以下式（I）的化合物，或其药学上可接受的盐、水合物、溶剂合物或前药，或其同位素变体、立体异构体或互变异构体。该发明涉及包括药物组合物在内的组合物，以及其相应的用途，涉及预防和治疗的方法。
• [EN] PYRAZOLEPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2009071706A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particularly, to a compound according to formula I: or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof or isotopic variants thereof, stereoisomers or tautomers thereof. The invention extends to compositions, including pharmaceutical compositions, and corresponding uses thereof, and methods of prophylaxis and treatment involving the same.

  本发明涉及一种抑制PDElA的化合物，PDElA是参与调节软骨降解、关节退化以及涉及此类降解和/或炎症的疾病的磷酸二酯酶，特别是根据式I的化合物：或其药学上可接受的盐、水合物、溶剂合物或前药，或其同位素变体、立体异构体或互变异构体。本发明还涉及包括药物组合物在内的组合物，以及其相应的用途和涉及相同的预防和治疗方法。
• SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
  申请人：PLAYER Mark R.

  公开号：US20120202856A1

  公开（公告）日：2012-08-09

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.

  本发明涉及苯并咪唑衍生物，包含它们的药物组合物以及它们在治疗由TRP M8调节的疾病和症状中的应用，例如炎症性疼痛、炎症性过敏症、炎症性过敏性疾病、神经病性疼痛、神经性寒冷触痛、炎症性体部过敏症、炎症性内脏过敏症、受冷加重的心血管疾病和受冷加重的肺部疾病。
• Ligand-Promoted C(sp³)−H Olefination en Route to Multi-functionalized Pyrazoles
  作者：Weibo Yang、Shengqing Ye、Yvonne Schmidt、Dean Stamos、Jin-Quan Yu

  DOI：10.1002/chem.201600704

  日期：2016.5.17

  A Pd‐catalyzed/N‐heterocycle‐directed C(sp3)−H olefination has been developed. The monoprotected amino acid ligand (MPAA) is found to significantly promote Pd‐catalyzed C(sp3)−H olefination for the first time. Cu(OAc)2 instead of Ag+ salts are used as the terminal oxidant. This reaction provides a useful method for the synthesis of alkylated pyrazoles.

  开发了Pd 催化/N 杂环定向的 C(sp 3 )−H 烯化反应。首次发现单保护氨基酸配体（MPAA）显着促进 Pd 催化的 C(sp 3 )−H 烯化反应。使用Cu(OAc) 2代替Ag +盐作为末端氧化剂。该反应为烷基化吡唑的合成提供了一种有用的方法。
• Palladium-catalyzed multi-acetoxylation of 1,3-disubstituted 1H-pyrazole-5-carboxylates via direct C(sp2)H or C(sp3)H bond activation
  作者：Jun Ding、Ying Guo、Ling-Yan Shao、Fei-Yi Zhao、Dao-Hua Liao、Hong-Wei Liu、Ya-Fei Ji

  DOI：10.1016/j.cclet.2016.04.007

  日期：2016.10

  1,3-disubstituted 1 H -pyrazole-5-carboxylate derivatives containing multiple potential reactive sites is described. Therein, the sequence of this process has been appropriately investigated. The protocol mainly provides the di- and tri-acetoxylated products for 1,3-diarylpyrazoles. Besides, it is found that the acetoxylation of C(sp 3 ) H bond is prior to that of C(sp 2 ) H bond under structurally

  摘要描述了钯催化的含多个潜在反应位点的1,3-二取代的1 H-吡唑-5-羧酸酯衍生物的多乙酰氧基化反应。其中，已经适当地研究了该过程的顺序。该协议主要提供1,3-二芳基吡唑的二乙酰氧基化产物和三乙酰氧基化产物。此外，发现在结构竞争性条件下，C（sp 3）H键的乙酰氧基化作用优先于C（sp 2）H键的乙酰化作用。